1. Home
  2. ELTK vs BOLD Comparison

ELTK vs BOLD Comparison

Compare ELTK & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eltek Ltd.

ELTK

Eltek Ltd.

N/A

Current Price

$8.07

Market Cap

62.5M

Sector

Technology

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.89

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTK
BOLD
Founded
1970
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Electrical Products
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
62.5M
60.8M
IPO Year
1998
2024

Fundamental Metrics

Financial Performance
Metric
ELTK
BOLD
Price
$8.07
$2.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
13.3K
255.3K
Earning Date
05-19-2026
05-06-2026
Dividend Yield
2.14%
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.18
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$48.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.30
$0.96
52 Week High
$11.59
$2.97

Technical Indicators

Market Signals
Indicator
ELTK
BOLD
Relative Strength Index (RSI) 43.38 72.94
Support Level $8.11 $2.39
Resistance Level $9.46 $2.97
Average True Range (ATR) 0.59 0.15
MACD -0.05 -0.01
Stochastic Oscillator 20.83 79.25

Price Performance

Historical Comparison
ELTK
BOLD

About ELTK Eltek Ltd.

Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: